ライフサイエンスコーパス: leucovorin

1 id (FA) and N(5)-formyltetrahydrofolic acid (leucovorin).

2 e HAI versus systemic bolus fluorouracil and leucovorin.

3 for 3 days before a 5-day course of FU plus leucovorin.

4 sease when they are added to flurouracil and leucovorin.

5 0.8% (five of 628) for bolus weekly 5-FU and leucovorin.

6 treatment with irinotecan, fluorouracil, and leucovorin.

7 e were similar to those for fluorouracil and leucovorin.

8 erved with infusional 5-FU or bolus 5-FU and leucovorin.

9 efractory to treatment with fluorouracil and leucovorin.

10 C85 at 50 mg/d and oral 5-FU with or without leucovorin.

11 important chemotherapy regime 5-fluorouracil/leucovorin.

12 IFL [irinotecan and bolus fluorouracil plus leucovorin]).

13 /- 0.01 mM; K(m(FA)), 0.17 +/- 0.02 mM; K(m (leucovorin)), 0.64 +/- 0.23 mM] transport by MRP4.

14 ow-affinity (K(m(FA)), 1.96 +/- 0.13 mM; K(m(leucovorin)), 1.74 +/- 0.65 mM) transport by MRP3.

15 (max (FA)), 0.68 +/- 0.14 nmol/mg/min; V(max(leucovorin)), 1.95 +/- 0.18 nmol/mg/min], low affinity [

16 began treatment with eniluracil (20 mg) and leucovorin (15 mg) (PO bid on days 1 through 3) and 5-FU

17 85 mg/m(2) oxaliplatin infusion over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over

18 nfusion (HAI) plus systemic fluorouracil and leucovorin, 2-year survival increased to 86%.

19 and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks

20 r square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bol

21 er square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bol

22 racil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given o

23 Each cycle of mFOLFOX6 consisted of racemic leucovorin 200 mg/m(2) or 400 mg/m(2), according to the

24 (IV) during 2 hours on day 1, hours 0 to 2; leucovorin 200 mg/m2 IV on days 1 and 2, hours 0 to 2; F

25 ned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin;

26 V(max(FA)), 1.71 +/- 0.05 nmol/mg/min; V(max(leucovorin)), 3.63 +/- 1.20 nmol/mg/min), low-affinity (

27 sion for 4 weeks followed by 1 week of rest; leucovorin 30 mg/m2 administered via intravenous bolus i

28 nfusion over 2 h, L-leucovorin 175 mg or D,L-leucovorin 350 mg infusion over 2 h, and 400 mg/m(2) bol

29 eceived mFOLFOX6 [oxaliplatin 85 mg/m(2) and leucovorin 400 mg/m(2) intravenously followed by fluorou

30 liplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and bolus fluorouracil 400 mg/m(

31 d on days 15 and 29: oxaliplatin 85 mg/m(2), leucovorin 400 mg/m(2), and fluorouracil 2,000 mg/m(2) i

32 n (180 mg/m(2)), bolus FU (400 mg/m(2)), and leucovorin (400 mg/m(2)) followed by a 46-hour infusion

33 platin, 85 mg/m(2); irinotecan, 180 mg/m(2); leucovorin, 400 mg/m(2); and fluorouracil, 400 mg/m(2) b

34 ens were bolus fluorouracil (5-FU), 5-FU and leucovorin, 5-FU and levamisole, and 5-FU, leucovorin, a

35 n of the MTD of 5-FU given with 776C85, oral leucovorin 50 mg/d on days 2 through 6 was added to dete

36 76C85 10 mg/d with i.v. 5-FU 20 mg/m2/d plus leucovorin 50 mg/d; 776C85 50 mg/d with 5-FU given orall

37 y intravenous [IV] bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-w

38 travenous (IV) bolus weekly for 6 weeks plus leucovorin 500 mg/m2 IV weekly for 6 weeks during each 8

39 preciably reversed in the presence of excess leucovorin, a hRFC substrate.

40 nd efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients

41 mpounds possessing synergistic activity with leucovorin against colorectal cancer cells.

42 higher response rate than 5-fluorouracil and leucovorin alone.

43 he combined XELOX and FOLFOX groups, and the leucovorin and fluorouracil groups.

44 idence that oxaliplatin plus capecitabine or leucovorin and fluorouracil is the standard of care for

45 mined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxalipla

46 significantly between patients who received leucovorin and fluorouracil versus those who received ca

47 capecitabine with or without oxaliplatin and leucovorin and fluorouracil with or without oxaliplatin

48 ecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin

49 r without oxaliplatin and those who received leucovorin and fluorouracil with or without oxaliplatin.

50 hemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil).

51 for the comparison of XELOX or FOLFOX versus leucovorin and fluorouracil, and was also similar for ca

52 milar for capecitabine-based regimens versus leucovorin and fluorouracil-based regimens (unadjusted p

53 Patients in the fluorouracil-plus-leucovorin and fluorouracil-plus-levamisole groups were

54 luoropyrimidine backbone was capecitabine or leucovorin and fluorouracil.

55 were: XELOX (oxaliplatin and capecitabine); leucovorin and fluorouracil; capecitabine; FOLFOX-4 (leu

56 Early intervention with the combination of leucovorin and glucarpidase is highly effective in patie

57 0089 assessed the relative contributions of leucovorin and levamisole in such patients.

58 nd scheduling, as well as biomodulation with leucovorin and methotrexate.

59 mice were given cisplatin or 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX), and their tumors we

60 oxic effects of 5-fluorouracil combined with leucovorin and to the thymidylate synthase inhibitor, ZD

61 id (FA) and N(5)-formyltetrahydrofolic acid (leucovorin) and that polyglutamylation of MTX abolishes

62 aliplatin plus bolus and infusional 5-FU and leucovorin, and 1.1% (three of 275) for oxaliplatin plus

63 g/m(2) oxaliplatin infusion over 2 h, 200 mg leucovorin, and 400 mg/m(2) bolus fluorouracil followed

64 Plasma MTX, leucovorin, and 5-methyltetrahydrofolate (5-mTHF) concen

65 plus cisplatin (IC), or FOLFOX (oxaliplatin, leucovorin, and bolus and infusional fluorouracil).

66 ceived two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiati

67 s of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiatio

68 and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment a

69 de, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated

70 y for trans-stimulation by pretreatment with leucovorin, and inhibition by N-hydroxysuccinimide metho

71 apy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, le

72 ) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in t

73 ) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in t

74 that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly impro

75 rior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI).

76 -line treatment and subsequent fluorouracil, leucovorin, and irinotecan with or without bevacizumab i

77 rred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplat

78 n) in study 20050203, FOLFIRI (fluorouracil, leucovorin, and irinotecan) in study 20050181, or best s

79 e that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus

80 rious combinations of adjuvant fluorouracil, leucovorin, and levamisole to determine the ability of t

81 d leucovorin, 5-FU and levamisole, and 5-FU, leucovorin, and levamisole.

82 cizumab to modified infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) 6 regimen for the a

83 n cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remain

84 -year survival with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better

85 andom assignment to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FOLFOX plus cetu

86 juvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assig

87 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy

88 luated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with se

89 th stage III CC treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regimen.

90 ed with second-line infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4; arm B) versus irin

91 icacy of adding bevacizumab to fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) for the adjuvant t

92 All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bev

93 th previous reports of either infusional FU, leucovorin, and oxaliplatin or capecitabine and oxalipla

94 Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan,

95 the cost and effectiveness of fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab

96 mFOLFOX6; ie, infusional/bolus fluorouracil, leucovorin, and oxaliplatin) for the adjuvant treatment

97 ned 1:1 to FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) in study 20050203, FOLFIRI

98 nts receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Centr

99 FOLFOX6 (mFOLFOX6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusional FU/leucov

100 adjuvant therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were randomly assigned to i

101 current standard treatment, 5-fluorouracil, leucovorin, and oxaliplatin, in this subgroup remains un

102 n, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevaciz

103 al Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin

104 or therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival

105 gery followed by postoperative fluorouracil, leucovorin, and radiotherapy, indicated a significant su

106 leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone.

107 77C, and V380C), inhibition was prevented by leucovorin, another hRFC substrate.

108 Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resec

109 MTX, FA, and leucovorin are subject to high capacity [V(max(MTX)), 0.

110 Both FA and leucovorin are subject to high-capacity (V(max(FA)), 1.7

111 en with biochemical modulation, such as with leucovorin, are indicated.

112 covorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorect

113 ished alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colore

114 of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy fo

115 bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and

116 Fluorouracil/leucovorin as the sole therapy for metastatic colorectal

117 9 cells treated with ZD9331 or 5fluorouracil/leucovorin, as demonstrated by cDNA microarray analyses.

118 ified FOLFIRINOX (oxaliplatin at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), an

119 /d with 5-FU given orally at 15 mg/m2/d with leucovorin at 50 mg/d.

120 have comparable activity to fluorouracil and leucovorin, but further studies are needed to assess whe

121 than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threateni

122 Children with FRAs were treated with oral leucovorin calcium (2 mg kg(-1) per day; maximum 50 mg p

123 iven these results, empirical treatment with leucovorin calcium may be a reasonable and non-invasive

124 studies of folate receptor autoimmunity and leucovorin calcium treatment in children with ASD are wa

125 -positive children with ASD may benefit from leucovorin calcium treatment.

126 m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of 5-fluorouraci

127 randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chem

128 The delivery of PV FUDR and FU with leucovorin can be performed with a high percentage of ex

129 d pyrimidines, including uracil:tegafur plus leucovorin, capecitabine, eniluracil plus oral 5-fluorou

130 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgi

131 dard adjuvant oxaliplatin, fluorouracil, and leucovorin chemotherapy (FOLFOX4) in patients with stage

132 PV FUDR and systemic fluorouracil (FU) with leucovorin chemotherapy.

133 herapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regim

134 onal arm of INT0116, a fluorouracil (FU) and leucovorin-containing chemoradiotherapy regimen, is a st

135 rinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life.

136 glucarpidase, inadequate initial increase in leucovorin dosing, and administration of glucarpidase mo

137 Leucovorin, due to its vitamin-like profile, has few sid

138 found that the combination of bortezomib and leucovorin enhanced caspase activation and increased apo

139 These data support leucovorin enhances the anti-cancer effect of bortezomib

140 in combination with i.v. 5-fluorouracil and leucovorin every 28 days.

141 e effects of postoperative fluorouracil plus leucovorin (five trials) or fluorouracil plus levamisole

142 nation chemotherapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (

143 tin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regim

144 ebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic

145 Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is th

146 ancer and have been treated with combination leucovorin, fluorouracil, and oxaliplatin (FOLFOX)-based

147 tuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) reg

148 ther oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plu

149 in and fluorouracil; capecitabine; FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin); and modified

150 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; f

151 oup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit

152 d improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens.

153 ), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX

154 t of CRC when combined with fluorouracil and leucovorin (FOLFOX).

155 itumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, acc

156 tment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without b

157 bination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4).

158 (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported i

159 f irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the

160 to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of

161 had received protracted infusion of 5-FU and leucovorin for treatment of metastatic colon cancer.

162 Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the r

163 il (FU) an attractive alternative to FU plus leucovorin (FU/LV) for the adjuvant treatment of colorec

164 ection include intravenous fluorouracil with leucovorin (FU/LV) or oral capecitabine.

165 l compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-li

166 olong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the sta

167 rimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothe

168 addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) i

169 efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in

170 sive-course fluorouracil (5FU) plus low-dose leucovorin given for 6 months following potentially cura

171 d clinical dose regimen of 25 mg/kg/day 5-FU/leucovorin given i.v., both treatments were equally effi

172 equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<

173 ents treated with irinotecan plus bolus 5-FU/leucovorin had a three-fold higher rate of treatment-ind

174 Although leucovorin had been shown to selectively spare normal bo

175 combination of irinotecan, fluorouracil, and leucovorin has also improved overall survival.

176 The combination of fluorouracil and leucovorin has until recently been standard therapy for

177 when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal can

178 receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of

179 to first-line irinotecan, fluorouracil, and leucovorin (IFL) significantly prolonged median survival

180 ith irinotecan, bolus fluorouracil (FU), and leucovorin (IFL).

181 ceive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and i

182 with irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or with bolus irinotecan

183 evacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with

184 CPDG2 rescue administered with thymidine and leucovorin in 20 patients is presented here.

185 , the prevalence of FRAs and the response to leucovorin in FRA-positive children has not been systema

186 ernational Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) st

187 alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.

188 was added to determine the MTD of 5-FU with leucovorin in the presence of 776C85.

189 e killing with complement and 5-fluorouracil/leucovorin in vivo, suggesting a new therapeutic approac

190 experiment, 5-FU treatment (with or without leucovorin) in combination with 131I-mAb A33 showed a st

191 s most apparent in the subgroup treated with leucovorin, in which the level of TS expression and resp

192 estigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in

193 IRINOX chemotherapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients wi

194 in the metastatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine

195 cytotoxic combinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as well as gemci

196 FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabin

197 sponse to chemotherapeutic regimens in which leucovorin is a component.

198 10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the refe

199 atment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluor

200 Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon

201 5-fluorouracil, often given with leucovorin, is the most commonly used drug in colorectal

202 v. MTX (regimens A and C v B), increased MTX-leucovorin (LCV) ratio (regimens A and C v B), and choic

203 irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (

204 y 2, weekly; arm C, 5-FU 600 mg/m2 with oral leucovorin (LV) 125 mg/m2 hourly for the preceding 4 hou

205 mbinations of oxaliplatin, fluorouracil (FU)/leucovorin (LV) and irinotecan.

206 adiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone.

207 tion of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with co

208 ine and when added to fluorouracil (FU) plus leucovorin (LV) in first-line therapy of metastatic colo

209 d effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients wit

210 vorin, and oxaliplatin) versus infusional FU/leucovorin (LV) in this setting.

211 ; or arm 3 (bolus-only arm), with bolus FU + leucovorin (LV) in two 5-day cycles before and after XRT

212 n with fluorouracil (FU) and with or without leucovorin (LV) in various regimens.

213 5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal

214 1) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agent

215 motherapy with uracil and tegafur (UFT) plus leucovorin (LV) may reduce costs and complications assoc

216 eived either oral uracil/ftorafur (UFT) plus leucovorin (LV) or standard intravenous (IV) fluorouraci

217 es weekly: the dose of AMT was decreased and leucovorin (LV) rescue was added after the DLT was obser

218 alone or surgery plus fluorouracil (FU) and leucovorin (LV) to develop multigene algorithms to quant

219 ur and uracil in a 1:4 molar ratio (UFT) and leucovorin (LV) to intravenous (IV) fluorouracil (5-FU)

220 een recommended together with high-dose (HD) leucovorin (LV) to treat patients at risk for methotrexa

221 helial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with meta

222 ) alone and in combination with i.v. calcium leucovorin (LV) were determined.

223 Protocol C-03 compared adjuvant 5-FU and leucovorin (LV) with adjuvant MOF.

224 ficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous

225 two irinotecan (CPT-11), fluorouracil (FU), leucovorin (LV), and oxaliplatin schedules in patients w

226 Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administere

227 trials as a single agent or biomodulated by leucovorin (LV).

228 11; group A) or Oxal, fluorouracil (FU), and leucovorin (LV; group B).

229 ith irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IF

230 n combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL).

231 X6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin), bFOL (bolus FU and lo

232 es in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4

233 omly assigned to bolus and infusional FU and leucovorin (LV5FU2), single-agent oxaliplatin, or the co

234 e (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a pe

235 ased therapy (either FU + levamisole or FU + leucovorin; n = 229) versus no postsurgical treatment (n

236 eks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of

237 before cycle 1; methotrexate 3.5 g/m(2) with leucovorin on weeks 1, 3, 5, 7, and 9; TMZ daily for 5 d

238 le to metabolize folinic acid (also known as leucovorin or 5-formyltetrahydrofolate), whose metabolic

239 r first-line fluoropyrimidines (fluorouracil/leucovorin or capecitabine, the latter only for metastat

240 ed venous infusion CT (n = 325), RT + FU +/- leucovorin or levamisole bolus CT (n = 1,695), or CT alo

241 were randomly assigned to bolus fluorouracil/leucovorin or protracted venous infusion fluorouracil.

242 and in combination with 5-fluorouracil plus leucovorin or with oxaliplatin.

243 us intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alo

244 vents consistent with those expected from FU/leucovorin- or IFL-based regimens were seen, as were mod

245 There is no advantage to leucovorin- or levamisole-containing regimens over bolus

246 In combination with 5-fluorouracil and leucovorin, oxaliplatin provides a higher response rate

247 eived 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed b

248 chaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prosp

249 bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) show

250 rvival are similar to those observed with FU/leucovorin/oxaliplatin combinations.

251 fewer adverse events than fluorouracil plus leucovorin (P<0.001).

252 of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, foll

253 of three chemotherapy regimens: the low-dose leucovorin plus FU (Mayo Clinic; LDLV) regimen, the high

254 U (Mayo Clinic; LDLV) regimen, the high-dose leucovorin plus FU (Roswell Park; HDLV) regimen, and the

255 whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.

256 oswell Park; HDLV) regimen, and the low-dose leucovorin plus levamisole plus FU (LDLV plus LEV) regim

257 FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for

258 val compared with intensive-course 5-FU plus leucovorin plus levamisole.

259 Since 2003, fluorouracil/leucovorin plus oxaliplatin (FOLFOX) has been the standa

260 h compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leuco

261 orin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan pl

262 A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associate

263 evel of TS expression and response to FU and leucovorin reached statistical significance (P =.034).

264 e (MTX/AZA) or intravenous methotrexate with leucovorin rescue (I.V. MTX) every 2 weeks for 6 months.

265 and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) ph

266 I.V. MTX with leucovorin rescue may also benefit some patients with re

267 intermediate-dose methotrexate (IDMTX) with leucovorin rescue on weeks 7, 10, 13, 16, 19, and 22 (re

268 domly assigned to receive high-dose MTX with leucovorin rescue or escalating dose MTX with PEG aspara

269 CPDG2, thymidine, and leucovorin rescue was highly effective in 20 patients at

270 es of vinblastine, methotrexate with calcium leucovorin rescue, and fluorouracil (VbMF).

271 py that included high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin, bleomycin, cy

272 ating dose MTX with PEG asparaginase without leucovorin rescue.

273 and methotrexate (400 mg/kg per cycle) with leucovorin rescue.

274 t change after adjustment for age or dose of leucovorin rescue.

275 e doses of intravenous (IV) glucarpidase and leucovorin rescue.

276 ose methotrexate total dose of 8.4 g/m2 with leucovorin rescue; thiotepa 35 mg/m2; vincristine 1.4 mg

277 treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-

278 Adjuvant chemoradiation with 5-fluorouracil/leucovorin significantly improves disease-free survival

279 Interestingly, leucovorin supplementation of a commonly used folate-def

280 treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and l

281 ich stands for folate utilization enzyme for leucovorin), that is hypersusceptible to antifolates.

282 olerated dose (MTD) of 5-FU, with or without leucovorin, that could be safely administered with 776C8

283 on could be detected between the addition of leucovorin to FU and the level of TS expression in the p

284 ropyrimidine dehydrogenase [DPD]), 5-FU, and leucovorin to simulate this schedule.

285 cetaxel, cisplatin, fluorouracil (5-FU), and leucovorin (TPFL5) induction chemotherapy for patients w

286 ents were equally efficacious, although 5-FU/leucovorin treatment started 7 days earlier.

287 al rates in comparison with fluorouracil and leucovorin treatment.

288 ompared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and

289 type of pre/postoperative chemotherapy (5-FU-leucovorin vs. FOLFOX/FOLFIRI vs. bevacizumab) (P=0.11)

290 of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe.

291 Systemic fluorouracil (5-FU) plus leucovorin was added to intrahepatic FUDR to prolong the

292 However, transport of the reduced folate leucovorin was not detected for either the wild-type or

293 Maintenance chemotherapy with 5-FU plus leucovorin was then given until disease progression.

294 y (capecitabine or infused fluouroracil plus leucovorin) was decided before randomisation.

295 Fluorouracil and leucovorin were administered before, during, and after r

296 then intravenous chemotherapy with 5-FU plus leucovorin were administered until maximal regression of

297 new agent oxaliplatin to high-dose 5FU plus leucovorin, which gave a median survival rate of 12.5 mo

298 CDB 402 of folinic acid, known clinically as leucovorin, which is a reduced form of the folic acid pr

299 Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boo

300 combination of irinotecan, fluorouracil and leucovorin with bolus doses of fluorouracil and leucovor